There are disclosed compounds that modulate or inhibit the enzymatic activity of indoleamine 2,3-dioxygenase (IDO), pharmaceutical compositions containing said compounds and methods of treating proliferative disorders, such as cancer, viral infections and/or inflammatory disorders utilizing the compounds of the invention.

The present invention is directed to compounds of the formula (I) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

##STR00001##

Provided herein are deuterated compounds and compositions useful in increasing PPARδ activity. The compounds and compositions provided herein are useful for the treatment of PPARδ related diseases (e.g., muscular diseases, vascular disease, demyelinating disease, and metabolic diseases).

The present invention relates to a compound represented by the general formula (I) (wherein the definition of each group has the same meaning as described in the specification). The compound is useful as preventive and/or therapeutic agent for KCNQ2-5 channel-related diseases.

##STR00001##

Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders. ##STR00001##

Described are RORγ modulators of the formula (I), or stereoisomers, tautomers, pharmaceutically acceptable salts, solvates, or prodrugs thereof, wherein all substituents are defined herein. Also provided are pharmaceutical compositions comprising the same. Such compounds and compositions are useful in methods for modulating RORγ activity in a cell and methods for treating a subject suffering from a disease or disorder in which the subject would therapeutically benefit from modulation of RORγ activity, for example, autoimmune and/or inflammatory disorders. ##STR00001##

The present invention relates to aroma chemical compositions containing 3,5-diethyl-2-propyl-tetrahydropyran, a 3,5-diethyl-2-propyl-dihydropyran or a 3,5-diethyl-2-propyl-pyran, a mixture of such compounds, a stereoisomer of one of these compounds, or a mixture of stereoisomers of one or more of these compounds. The invention further relates to a method for preparing such compounds, stereoisomers or mixtures thereof, to the composition obtainable by this method, to the use of such compounds as an aroma chemical or for modifying the scent character of a fragranced composition; and to a method for preparing a fragranced composition or for modifying the scent character of a fragranced composition using said compounds. Moreover, the invention relates to 3,5-diethyl-2-propyl-tetrahydropyran, to its stereoisomers and to mixtures of these stereoisomers.

The present invention relates to aroma chemical compositions containing 3,5-diethyl-2-propyl-tetrahydropyran, a 3,5-diethyl-2-propyl-dihydropyran or a 3,5-diethyl-2-propyl-pyran, a mixture of such compounds, a stereoisomer of one of these compounds, or a mixture of stereoisomers of one or more of these compounds. The invention further relates to a method for preparing such compounds, stereoisomers or mixtures thereof, to the composition obtainable by this method, to the use of such compounds as an aroma chemical or for modifying the scent character of a fragranced composition; and to a method for preparing a fragranced composition or for modifying the scent character of a fragranced composition using said compounds. Moreover, the invention relates to 3,5-diethyl-2-propyl-tetrahydropyran, to its stereoisomers and to mixtures of these stereoisomers.

Compounds of the formula I, ##STR00001##
in which Y.sup.1 denotes —O— or —CH.sub.2—, and the groups R.sup.1, L.sup.1 to L.sup.6 and X.sup.1 have the meanings indicated in claim 1. A process for the preparation thereof, and liquid-crystalline media comprising at least one compound of the formula I and electro-optical displays containing a liquid-crystalline medium this type. The compounds of the formula I include, as structural element, a combination of a 1,4-substituted cyclohexene ring besides a dioxane or tetrahydropyran ring and a substituted biphenyl group.

Compounds of the formula I, ##STR00001##
in which Y.sup.1 denotes —O— or —CH.sub.2—, and the groups R.sup.1, L.sup.1 to L.sup.6 and X.sup.1 have the meanings indicated in claim 1. A process for the preparation thereof, and liquid-crystalline media comprising at least one compound of the formula I and electro-optical displays containing a liquid-crystalline medium this type. The compounds of the formula I include, as structural element, a combination of a 1,4-substituted cyclohexene ring besides a dioxane or tetrahydropyran ring and a substituted biphenyl group.